BioTuesdays

Tag - Jotin Marango

Aptevo Therapeutics

Roth start Aptevo at buy; PT $12

Roth Capital Partners initiated coverage of Aptevo Therapeutics (NASDAQ:APVO) with a “buy” rating and price target of $12. The stock closed at $3.28 on April 11. “In our view, Aptevo remains under the Street’s...

GlycoMimetics

Roth ups GlycoMimetics PT to $35

Roth Capital Partners raised its price target for GlycoMimetics (NASDAQ:GLYC) to $35 from $25 after the company agreed with the Dutch hematological oncology foundation, HOVON, to move towards a 140-patient study of GMI...

GlycoMimetics

Roth starts GlycoMimetics at buy, PT $25

Roth Capital Partners initiated coverage of GlycoMimetics (NASDAQ:GLYC) with a “buy” rating and $25 price target. The stock closed at $10.52 on Oct. 23. “Our bull thesis on GlycoMimetics is driven by the GMI-1271...